Revision as of 18:33, 16 February 2012 editBeetstra (talk | contribs)Edit filter managers, Administrators172,071 edits Saving copy of the {{drugbox}} taken from revid 453535330 of page 5-Methyl-MDA for the Chem/Drugbox validation project (updated: 'CAS_number'). |
Latest revision as of 22:12, 11 January 2025 edit Arthurfragoso (talk | contribs)Extended confirmed users, Template editors4,591 edits dark mode fix |
Line 1: |
Line 1: |
|
|
{{short description|Chemical compound}} |
|
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}} |
|
|
{{Drugbox |
|
{{Drugbox |
|
|
| Verifiedfields = changed |
|
| verifiedrevid = 407465455 |
|
| verifiedrevid = 477225266 |
|
| IUPAC_name = 1-(7-methyl-1,3-benzodioxol-5-yl)propan-2-amine |
|
| IUPAC_name = 1-(7-methyl-1,3-benzodioxol-5-yl)propan-2-amine |
|
| image = 5-Methyl-MDA.svg |
|
| image = 5-Methyl-MDA.svg |
|
|
| image_class = skin-invert-image |
|
|
|
|
|
<!--Clinical data--> |
|
<!--Clinical data--> |
|
| tradename = |
|
| tradename = |
|
| pregnancy_category = |
|
| pregnancy_category = |
|
|
| legal_CA = Schedule I |
|
| legal_status = Uncontrolled <small>(but may be covered under the ] in the ] and under similar bills in other countries)</small> |
|
|
|
| legal_DE = NpSG |
|
|
| legal_UK = Class A |
|
|
| legal_US = analogue |
|
|
| legal_US_comment =(possibly, if human consumption intent can be proven) |
|
| routes_of_administration = ] |
|
| routes_of_administration = ] |
|
|
|
|
Line 15: |
Line 21: |
|
| metabolism = |
|
| metabolism = |
|
| elimination_half-life = |
|
| elimination_half-life = |
|
| excretion = |
|
| excretion = |
|
|
|
|
|
<!--Identifiers--> |
|
<!--Identifiers--> |
|
|
| CAS_number_Ref = {{cascite|changed|??}} |
|
| CAS_number = <!-- blanked - oldvalue: 749191-14-8 --> |
|
| CAS_number = 749191-14-8 |
|
| CAS_supplemental = <br />204916-89-2 (]) |
|
| CAS_supplemental = <br />204916-89-2 (]) |
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
|
| UNII = 10R3PP3FVM |
|
| ATC_prefix = none |
|
| ATC_prefix = none |
|
| ATC_suffix = |
|
| ATC_suffix = |
Line 30: |
Line 39: |
|
<!--Chemical data--> |
|
<!--Chemical data--> |
|
| C=11 | H=15 | N=1 | O=2 |
|
| C=11 | H=15 | N=1 | O=2 |
|
| molecular_weight = 193.242 g/mol |
|
|
| smiles = O2COc1c2cc(CC(N)C)cc1C |
|
| smiles = O2COc1c2cc(CC(N)C)cc1C |
|
| InChI = 1/C11H15NO2/c1-7-3-9(4-8(2)12)5-10-11(7)14-6-13-10/h3,5,8H,4,6,12H2,1-2H3 |
|
|
| InChIKey = OLENSVFSNAULML-UHFFFAOYAY |
|
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI = 1S/C11H15NO2/c1-7-3-9(4-8(2)12)5-10-11(7)14-6-13-10/h3,5,8H,4,6,12H2,1-2H3 |
|
| StdInChI = 1S/C11H15NO2/c1-7-3-9(4-8(2)12)5-10-11(7)14-6-13-10/h3,5,8H,4,6,12H2,1-2H3 |
Line 39: |
Line 45: |
|
| StdInChIKey = OLENSVFSNAULML-UHFFFAOYSA-N |
|
| StdInChIKey = OLENSVFSNAULML-UHFFFAOYSA-N |
|
}} |
|
}} |
|
|
|
|
|
'''5-Methyl-3,4-methylenedioxyamphetamine''' ('''5-Methyl-MDA''') is an ] and ] ] of the ] class. It is a ]-]ated ] of ] and a ] of ].<ref name="pmid9526575">{{cite journal | vauthors = Parker MA, Marona-Lewicka D, Kurrasch D, Shulgin AT, Nichols DE | title = Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA) | journal = Journal of Medicinal Chemistry | volume = 41 | issue = 6 | pages = 1001–5 |date=March 1998 | pmid = 9526575 | doi = 10.1021/jm9705925 }}</ref> |
|
|
|
|
|
==Effects and research== |
|
|
{{contradict section|date=June 2016}} |
|
|
{{primary sources| section|date=June 2016}} |
|
|
] studies showed that 5-methyl-MDA substitutes for MDA, ], and ], but not ], suggesting that it produces a mix of entactogen and hallucinogenic effects without any ] effects.{{cn|date=May 2019}} |
|
|
|
|
|
5-Methyl-MDA acts as a ] (SSRA) with ] values of 107nM, 11,600nM, and 1,494nM for ], ], and ] efflux.<ref name="pmid9526575" /> It is over 5 times more potent than MDA in vitro assays, with a suitable active dose possibly in vivo being around 15–25 mg.<ref name="pmid9526575" /> Subsequent testing in vivo, however, has found that it is not as potent as once thought and is active at at least 100 mg. ] is also much more potent than MDA, but is not quite as potent as 5-methyl-MDA.<ref name="pmid9526575" /> ] (also known as Madam-6) is mostly inactive, likely due to ].<ref name="pmid9526575" /><ref></ref> |
|
|
|
|
|
Recent research has used data on 2-methyl-MDA and 5-methyl-MDA to help guide computer modeling of the ] complex.<ref name="pmid18354055">{{cite journal | vauthors = Walline CC, Nichols DE, Carroll FI, Barker EL | title = Comparative molecular field analysis using selectivity fields reveals residues in the third transmembrane helix of the serotonin transporter associated with substrate and antagonist recognition | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 325 | issue = 3 | pages = 791–800 |date=June 2008 | pmid = 18354055 | pmc = 2637348 | doi = 10.1124/jpet.108.136200 }}</ref> |
|
|
|
|
|
==Legal status== |
|
|
5-Methyl-MDA is not scheduled by the ]' ].<ref name="UNCPS">{{Cite web |url=https://www.unodc.org/unodc/en/commissions/CND/conventions.html |title=Convention on Psychotropic Substances, 1971 |access-date=2016-06-09 |archive-date=2022-01-19 |archive-url=https://web.archive.org/web/20220119014500/http://www.unodc.org/unodc/en/commissions/CND/conventions.html |url-status=dead }}</ref> |
|
|
|
|
|
===United States=== |
|
|
5-Methyl-MDA is not ] at the ] in the ],<ref name="PART 1308 — SCHEDULES OF CONTROLLED SUBSTANCES - 1308.11 Schedule I">{{Cite web |url=http://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm |title=§1308.11 Schedule I. |access-date=2016-06-09 |archive-date=2009-08-27 |archive-url=https://web.archive.org/web/20090827043725/http://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm |url-status=dead }}</ref> but it is possible that 5-Methyl-MDA could legally be considered an ] of ], in which case, sales or ] could potentially be prosecuted under the ].<ref></ref> |
|
|
|
|
|
== References == |
|
|
{{Reflist}} |
|
|
|
|
|
{{Entactogens}} |
|
|
{{Hallucinogens}} |
|
|
{{Monoamine releasing agents}} |
|
|
{{Serotonin receptor modulators}} |
|
|
{{Phenethylamines}} |
|
|
|
|
|
{{DEFAULTSORT:Methyl-MDA, 5-}} |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |